Search for other papers by Elham Abbasi in
Current site
Google Scholar
PubMed
Search for other papers by Hossein Goudarzi in
Current site
Google Scholar
PubMed
Search for other papers by Ali Hashemi in
Current site
Google Scholar
PubMed
Search for other papers by Alireza Salimi Chirani in
Current site
Google Scholar
PubMed
Department of Microbiology, Faculty of Medicine, Golestan University of Medical Sciences,
Search for other papers by Abdollah Ardebili in
Current site
Google Scholar
PubMed
Search for other papers by Mehdi Goudarzi in
Current site
Google Scholar
PubMed
Search for other papers by Javad Yasbolaghi Sharahi in
Current site
Google Scholar
PubMed
Search for other papers by Sara Davoudabadi in
Current site
Google Scholar
PubMed
Search for other papers by Ghazaleh Talebi in
Current site
Google Scholar
PubMed
Search for other papers by Narjes Bostanghadiri in
Current site
Google Scholar
PubMed
Abstract
A major challenge in the treatment of infections has been the rise of extensively drug resistance (XDR) and multidrug resistance (MDR) in Acinetobacter baumannii. The goals of this study were to determine the pattern of antimicrobial susceptibility, blaOXA and carO genes among burn-isolated A. baumannii strains. In this study, 100 A. baumannii strains were isolated from burn patients and their susceptibilities to different antibiotics were determined using disc diffusion testing and broth microdilution. Presence of carO gene and OXA-type carbapenemase genes was tested by PCR and sequencing. SDS-PAGE was done to survey CarO porin and the expression level of carO gene was evaluated by Real-Time PCR. A high rate of resistance to meropenem (98%), imipenem (98%) and doripenem (98%) was detected. All tested A. baumannii strains were susceptible to colistin. The results indicated that 84.9% were XDR and 97.9% of strains were MDR. In addition, all strains bore blaOXA-51 like and blaOXA-23 like and carO genes. Nonetheless, blaOXA-58 like and blaOXA-24 like genes were harbored by 0 percent and 76 percent of strains, respectively. The relative expression levels of the carO gene ranged from 0.06 to 35.01 fold lower than that of carbapenem-susceptible A. baumannii ATCC19606 and SDS – PAGE analysis of the outer membrane protein showed that all 100 isolates produced CarO. The results of current study revealed prevalence of blaOXA genes and changes in carO gene expression in carbapenem resistant A.baumannii.
-
[1]
Subramaniyan A, Nair, S, Joseph, NM, Kanungo, R. Profile of multidrug resistant Acinetobacter baumannii infections among hospitalized patients. J Med Sci Clin Res 2017; 5: 23111–23115.
-
[2]
Zhao SY, Jiang DY, Xu PC, Zhang YK, Shi HF, Cao Hl, et al. An investigation of drug-resistant Acinetobacter baumannii infections in a comprehensive hospital of East China. Ann Clin Microbiol Antimicrob 2015; 3(14): 7.
-
[3]
Kempf M, Rolain JM. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int J Antimicrob Agents 2012; 39: 105–114.
-
[4]
Gholipourmalekabadi M, Bandehpour M, Mozafari M, Hashemi A, Ghanbarian H, Sameni M, et al. Decellularized human amniotic membrane: more is needed for an efficient dressing for protection of burns against antibiotic-resistant bacteria isolated from burn patients. Burns 2015; 41: 1488–1497.
-
[5]
Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006; 12: 826–836.
-
[6]
Lee Y, Kim CK, Lee H, Jeong SH, Yong D, Lee K. A novel insertion sequence, ISAba10, inserted into ISAba1 adjacent to the bla OXA-23 gene and disrupting the outer membrane protein gene carO in Acinetobacter baumannii. Antimicrob Agents Chemother 2011; 55: 361–363.
-
[7]
Quale J, Bratu S, Landman D, Heddurshetti R. Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City. Clin Infect Dis 2003; 37: 214–220.
-
[8]
Dalla-Costa LM, Coelho JM, Souza HA, Castro ME, Stier CJ, Bragagnolo KL, et al. Outbreak of carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme in Curitiba, Brazil. J Clin Microbiol 2003; 41: 3403–3406.
-
[9]
Higgins PG, Pérez-Llarena FJ, Zander E, Fernández A, Bou G, Seifert H. OXA-235, a novel class D β-lactamase involved in resistance to carbapenems in Acinetobacter baumannii. Antimicrob Agents Chemother 2013; 57: 2121–2126.
-
[10]
Mussi MA, Relling VM, Limansky AS, Viale AM. CarO, an Acinetobacter baumannii outer membrane protein involved in carbapenem resistance, is essential for L‐ornithine uptake. FEBS lett 2007; 581: 5573–5578.
-
[11]
Catel-Ferreira M, Coadou G, Molle V, Mugnier P, Nordmann P, Siroy A et al. Structure–function relationships of CarO, the carbapenem resistance-associated outer membrane protein of Acinetobacter baumannii. J Antimicrob Chemother 2011; 66: 2053–2056.
-
[12]
Fonseca EL, Scheidegger E, Freitas FS, Cipriano R, Vicente ACP. Carbapenem-resistant Acinetobacter baumannii from Brazil: role of carO alleles expression and bla OXA-23 gene. BMC Microbiol 2013; 13: 245.
-
[13]
Mussi MA, Limansky AS, Relling V, Ravasi P, Arakaki A, Actis LA, et al. Horizontal gene transfer and assortative recombination within the Acinetobacter baumannii clinical population provides genetic diversity at the single carO gene encoding a major outer membrane protein channel. J Bacteriol 2011; 193: 4736–4748.
-
[14]
Salehi B, Goudarzi H, Nikmanesh B, Houri H, Alavi-Moghaddam M, Ghalavand Z. Emergence and characterization of nosocomial multidrug-resistant and extensively drug-resistant Acinetobacter baumannii isolates in Tehran, Iran. J Infect Chemother 2018; 24: 515–523.
-
[15]
Nafarieh T, Bandehpour M, Hashemi A, Taheri S, Yardel V, Jamaati H, et al. Identification of antigens from nosocomial Acinetobacter baumannii clinical isolates in sera from ICU staff and infected patients using the antigenome technique. World J Microbiol Biotechnol 2017; 33: 189.
-
[16]
La Scola B, Gundi VA, Khamis A, Raoult D. Sequencing of the rpoB gene and flanking spacers for molecular identification of Acinetobacter species. J Clin Microbiol 2006; 44: 827–832.
-
[17]
Patel JB. Performance standards for antimicrobial susceptibility testing. Clinical and Laboratory Standards Institute; 2017.
-
[18]
Heidary M, Bahramian A, Hashemi A, Goudarzi M, Omrani VF, Eslami G, et al. Detection of acrA, acrB, aac (6′)-Ib-cr, and qepA genes among clinical isolates of Escherichia coli and Klebsiella pneumoniae. Acta Microbiol Immunol Hung 2016; 64: 63–69.
-
[19]
Lee Y, Yum JH, Kim CK, Yong D, Jeon EH, Jeong SH, et al. Role of OXA-23 and AdeABC efflux pump for acquiring carbapenem resistance in an Acinetobacter baumannii strain carrying the blaOXA-66 gene. Ann Clin Lab Sci 2010; 40: 43–48.
-
[20]
Zander E, Chmielarczyk A, Heczko P, Seifert H, Higgins PG. Conversion of OXA-66 into OXA-82 in clinical Acinetobacter baumannii isolates and association with altered carbapenem susceptibility. J Antimicrob Chemother 2012; 68: 308–311.
-
[21]
Chang Y, Luan G, Xu Y, Wang Y, Shen M, Zhang C et al. Characterization of carbapenem-resistant Acinetobacter baumannii isolates in a Chinese teaching hospital. Front Microbiol 2015; 6: 910.
-
[22]
Mohammadi F, Goudarzi H, Hashemi A, Nojookambari NY, Khoshnood S, Sabzehali F. Detection of ISAba1 in Acinetobacter baumannii strains carrying OXA genes isolated from Iranian burns patients. Pediatr Infect Dis J 2017; 5 e39307.
-
[23]
Lu PL, Doumith M, Livermore DM, Chen TP, Woodford N. Diversity of carbapenem resistance mechanisms in Acinetobacter baumannii from a Taiwan hospital: spread of plasmid-borne OXA-72 carbapenemase. J Antimicrob Chemother 2009; 63: 641–647.
-
[24]
Bahador A, Taheri M, Pourakbari B, Hashemizadeh Z, Rostami H, Mansoori N, et al. Emergence of rifampicin, tigecycline, and colistin-resistant Acinetobacter baumannii in Iran; spreading of MDR strains of novel International Clone variants. Microb Drug Resist 2013; 19: 397–406.
-
[25]
Shoja S, Moosavian M, Rostami S, Farahani A, Peymani A, Ahmadi K, et al. Dissemination of carbapenem-resistant Acinetobacter baumannii in patients with burn injuries. J Chin Med Assoc 2017; 80: 245–252.
-
[26]
Rezaei A, Fazeli H, Moghadampour M, Halaji M, Faghri J. Determination of antibiotic resistance pattern and prevalence of OXA-type carbapenemases among Acinetobacter baumannii clinical isolates from inpatients in Isfahan, central Iran. Infez Med Rivista Periodica di Eziologia, Epidemiologia, Diagnostica, Clinica e Terapia delle Patologie Infettive 2018; 26: 61–66.
-
[27]
Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51: 3471–3484.
-
[28]
Singkham-in U, Chatsuwan T. In vitro activities of carbapenems in combination with amikacin, colistin or fosfomycin against carbapenem-resistant Acinetobacter baumannii clinical isolates. Diagn Microbiol Infect Dis 2018; 91: 169–174.
-
[29]
Mirshekar M, Shahcheraghi F, Azizi O, Solgi H, Badmasti F. Diversity of class 1 integrons, and disruption of carO and dacD by insertion sequences among Acinetobacter baumannii isolates in Tehran, Iran. Microb Drug Resist 2018; 24: 359–366.
-
[30]
Mussi MA, Limansky AS, Viale AM. Acquisition of resistance to carbapenems in multidrug-resistant clinical strains of Acinetobacter baumannii: natural insertional inactivation of a gene encoding a member of a novel family of β-barrel outer membrane proteins. Antimicrob Agents Chemother 2005; 49: 1432–1440.
-
[31]
Morán-Barrio J, Cameranesi MM, Relling V, Limansky AS, Brambilla L, Viale AM. The Acinetobacter outer membrane contains multiple specific channels for carbapenem β-lactams as revealed by kinetic characterization analyses of imipenem permeation into Acinetobacter baylyi cells. Antimicrob Agents Chemother 2017; 61: e01737–1716.
-
[32]
Xiao SZ, Chu HQ, Han LZ, Zhang ZM, Li B, Zhao L, et al. Resistant mechanisms and molecular epidemiology of imipenem-resistant Acinetobacter baumannii. Mol Med Rep 2016; 14: 2483–2488.
-
[33]
Cardoso JP, Cayô R, Girardello R, Gales AC. Diversity of mechanisms conferring resistance to β-lactams among OXA-23–producing Acinetobacter baumannii clones. Diagn Microbiol Infect Dis 2016; 85: 90–97.
-
[34]
Costa S, Woodcock J, Gill M, Wise R, Barone A, Caiaffa H, Levin AS. Outer-membrane proteins pattern and detection of β-lactamases in clinical isolates of imipenem-resistant Acinetobacter baumannii from Brazil. Int J Antimicrob Agents 2000; 13: 175–182.
-
[35]
Héritier C, Poirel L, Lambert T, Nordmann P. Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 2005; 49: 3198–3202.
-
[36]
Hu WS, Yao SM, Fung CP, Hsieh YP, Liu CP, Lin JF. An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51: 3844–3852.
-
[37]
Walther-Rasmussen J, Høiby N. OXA-type carbapenemases. Int J Antimicrob Agents 2006; 57: 373–383.
-
[38]
Novovic K, Mihajlovic S, Vasiljevic Z, Filipic B, Begovic J, Jovcic B. Carbapenem-resistant Acinetobacter baumannii from Serbia: revision of CarO classification. PloS One 2015; 10 e0122793.
-
[39]
Mostachio AK, Levin AS, Rizek C, Rossi F, Zerbini J, Costa SF. High prevalence of OXA-143 and alteration of outer membrane proteins in carbapenem-resistant Acinetobacter spp. isolates in Brazil. Int J Antimicrob Agents 2012; 39: 396–401.
Editorial Office:
Akadémiai Kiadó Zrt.
Budafoki út 187-187, A/3, H-1117 Budapest, Hungary
Editorial Correspondence:
Acta Microbiologica et Immunologica Hungarica
Institute of Medical Microbiology
Semmelweis University
P.O. Box 370
H-1445 Budapest, Hungary
Phone: + 36 1 459 1500 ext. 56101
Fax: (36 1) 210 2959
E-mail: amih@med.semmelweis-univ.hu
Indexing and Abstracting Services:
- Biological Abstracts
- BIOSIS Previews
- CAB Abstracts
- CABELLS Journalytics
- Chemical Abstracts
- Global Health
- Index Medicus
- Index Veterinarius
- Medline
- Referativnyi Zhurnal
- SCOPUS
- Science Citation Index Expanded
| 2023 | |
|---|---|
| Web of Science | |
| Journal Impact Factor | 1.3 |
| Rank by Impact Factor | Q4 (Immunology) |
| Journal Citation Indicator | 0.31 |
| Scopus | |
| CiteScore | 2.3 |
| CiteScore rank | Q3 (Infectious Diseases) |
| SNIP | 0.389 |
| Scimago | |
| SJR index | 0.308 |
| SJR Q rank | Q3 |
| Acta Microbiologica et Immunologica Hungarica | |
|---|---|
| Publication Model | Hybrid |
| Submission Fee | none |
| Article Processing Charge | 1100 EUR/article (only for OA publications) |
| Regional discounts on country of the funding agency | World Bank Lower-middle-income economies: 50% World Bank Low-income economies: 100% |
| Further Discounts | Editorial Board / Advisory Board members: 50% Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100% |
| Subscription fee 2025 | Online subsscription: 772 EUR / 848 USD Print + online subscription: 860 EUR / 944 USD |
| Subscription Information | Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content. |
| Purchase per Title | Individual articles are sold on the displayed price. |
| Acta Microbiologica et Immunologica Hungarica | |
|---|---|
| Language | English |
| Size | A4 |
| Year of Foundation |
1954 |
| Volumes per Year |
1 |
| Issues per Year |
4 |
| Founder | Magyar Tudományos Akadémia |
| Founder's Address |
H-1051 Budapest, Hungary, Széchenyi István tér 9. |
| Publisher | Akadémiai Kiadó |
| Publisher's Address |
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245. |
| Responsible Publisher |
Chief Executive Officer, Akadémiai Kiadó |
| ISSN | 1217-8950 (Print) |
| ISSN | 1588-2640 (Online) |
Monthly Content Usage
| Abstract Views | Full Text Views | PDF Downloads | |
|---|---|---|---|
| Apr 2024 | 43 | 0 | 0 |
| May 2024 | 68 | 0 | 0 |
| Jun 2024 | 80 | 0 | 1 |
| Jul 2024 | 84 | 0 | 0 |
| Aug 2024 | 38 | 0 | 0 |
| Sep 2024 | 90 | 0 | 0 |
| Oct 2024 | 53 | 0 | 0 |
Copyright Akadémiai Kiadó AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.